Sumary of Stimulating Innate Immunity Stops SARS-CoV-2 Infection:
- A new study, available now to read online and due to publish in the Journal of Experimental Medicine next year, offers an approach that could make a vital addition to our current arsenal of anti-SARS-CoV-2 countermeasures.
- al have identified an antiviral drug that activates the innate immune system and appears to have strong prophylactic and therapeutic potential in mice, meaning it could both prevent and treat Covid-19 in humans.
- Their findings form the latest contribution to a growing body of work on SARS-CoV-2 and innate immunity, the body’s first line of defense against pathogens.
- But a series of papers I have analyzed at length in my SARS-CoV-2 immune suppression series for Forbes shows that it is not adaptive immunity but innate immunity that the virus antagonizes so rigorously in the early days of infection.
- If a drug can stimulate innate immunity and generate protection before SARS-CoV-2 has the opportunity to tamper, it could protect high-risk individuals from severe illness, persistent infection, and death.
- Innate immunity is driven by the identification of pathogen-associated molecular patterns, or PAMPs, by pattern recognition receptors that have evolved over the course of the millennia-long battle between viruses and humans.
- Some of the most prominent pattern recognition receptors include toll-like receptors and retinoic acid-inducible gene I (RIG-I)-like receptors.
- Detection of PAMPs by these receptors is what activates the signaling pathways that induce production of interferons, interferon-stimulated genes, and inflammatory cytokines, which in turn trigger the adaptive immune response.